Risk factors for failure of bilateral sentinel lymph node mapping in early-stage cervical cancer

Background: The objective of this study was to determine clinical, tumoral and surgical factors associated with successful bilateral sentinel lymph node mapping (SBM) in early-stage cervical cancer. Methods: We performed an ancillary work on the data of two prospective trials on SLN biopsy for FIGO IA-IIA cervical cancer (SENTICOL I & II). Patients having Sentinel lymph node (SLN) mapping for earlystage cervical cancer were included between 2005 and 2012 from 28 French oncologic centers. SLN was detected by a combined labeling technique (blue and isotopic). Results: 405 patients were included for analysis: SLNs were identified on at least one side of the pelvis in 381 patients (94.1%) and bilaterally in 326 patients (80.5%). The mean age was 45.4 years [22-85 years]. Most patients had IB1 pathologic FIGO 2018 stage (81.3%) and squamous cell carcinoma (71%). Surgeries were mainly performed by minimally invasive approach (368 patients - 90.9%). By multivariate analysis, lower SBM rate was significantly associated with Age >= 70 years (ORa = 0.02, 95%CI = [0.001-0.28], p = 0.004), tumor size larger than 20 mm (ORa = 0.46,95%Cl = [0.21-0.99], p = 0.048) and Body-mass index higher than 30 kg/m 2 (ORa = 0.28, 95%Cl = [0.12-0.65], p = 0.003). SBM rate was significantly higher in high skills centers (>5patients/year) (ORa = 8.05, 95%Cl = [2.06-31.50], p = 0.003) and in SENTICOL II (2009-2012) compared to SENTICOL I (2005-2007) (ORa = 2.6, 95%Cl = [1.23-5.51], p = 0.01). Conclusions: In early-stage cervical cancer, bilateral SLN detection rates is lower in patients aged more than 70years, patients with BMI>30 kg/m(2) and larger tumor >20 mm whereas stronger experience of SLN biopsy technique improves bilateral SLN detection. (C) 2019 Elsevier Inc. All rights reserved.